Protective shield against HIV drug resistance

HIV Drug Resistance: What You Need to Know About Treatment Options

Nico Varela monogram
Nico Varela in Health & Wellness October 2026 • 4 min read.

"Understanding transmitted drug resistance, treatment strategies, and the future of HIV care."


The ongoing fight against HIV has been greatly aided by antiretroviral therapy (ART), turning what was once a deadly disease into a manageable chronic condition. However, the virus's ability to evolve and develop resistance to medications remains a significant hurdle. Understanding HIV drug resistance is essential for effective treatment and preventing the spread of resistant strains.

HIV drug resistance occurs when the virus mutates, altering its genetic structure in ways that reduce the effectiveness of antiretroviral drugs. This can happen when a person doesn't take their medication consistently, allowing the virus to replicate and potentially develop resistance. Additionally, some people may become infected with a strain of HIV that is already resistant to certain drugs, known as transmitted drug resistance (TDR).

This article explores the latest research and insights into HIV drug resistance, providing an overview of the challenges, treatment options, and future directions in this ever-evolving field. We'll delve into recent studies presented at medical conferences, offering accessible explanations of complex findings and practical implications for people living with HIV.

AI Search Multiple angles on this topic

Measuring Resistance

The HIV Drug Resistance Database at Stanford is a curated resource containing nearly all published HIV reverse transcriptase and protease sequences, supporting research into evolutionary and drug-related variation in anti-HIV therapy targets. The CDC's CADRE data can measure resistance to dolutegravir and other antiretroviral drugs, identify risk factors, and inform treatment choices when resistance is detected. WHO reports that acquired resistance to dolutegravir, a cornerstone of recommended first- and second-line therapy, may be higher than anticipated among people with extensive prior treatment experience, although more than 90% of patients achieve sustained treatment success.

Four Decades of Progress

A narrative review of HIV therapy milestones begins with the introduction of zidovudine in 1987 and extends through highly active antiretroviral therapy and recent long-acting injectable agents. Historical overviews identify AZT, also called zidovudine, as the first HIV treatment approved by the FDA and introduced in 1987. HAART marked a breakthrough by combining multiple drugs to control HIV, while modern treatment history now includes long-acting medications.

The Prevalence and Impact of Transmitted Drug Resistance (TDR)

Protective shield against HIV drug resistance

Transmitted drug resistance (TDR) is a significant concern in HIV management. Studies from around the world provide a glimpse into the varying rates of TDR and its potential impact on treatment outcomes. A study conducted in the Philippines, for example, found a TDR rate of 6.3% among newly diagnosed individuals. This highlights the importance of baseline drug resistance testing in certain populations.

The Philippine study also revealed that all cases of TDR were associated with the CRF01_AE subtype, suggesting a possible link between specific HIV subtypes and resistance. This finding underscores the need for continued surveillance and tailored prevention efforts.

  • Global Variations: TDR rates vary significantly across different regions and populations. Understanding these variations is crucial for informing treatment guidelines and resource allocation.
  • Subtype Associations: Certain HIV subtypes may be more prone to drug resistance. Further research is needed to fully understand these associations and their implications for treatment strategies.
  • Public Health Impact: TDR can compromise the effectiveness of first-line ART regimens, potentially leading to treatment failure and increased healthcare costs.
AI Search Multiple angles on this topic

Expanding ART Access

WHO reports that 31.6 million people were accessing antiretroviral therapy in 2024. This was an increase from 7.7 million people accessing ART in 2010. The figures show the continuing expansion of treatment access over that period.

Limits of the Evidence

WHO reports an increase in HIV drug resistance to dolutegravir, despite dolutegravir's central role in recommended treatment. However, only a few countries have reported survey data to WHO to date. That limited reporting means the available evidence does not yet provide comprehensive global coverage.

Strategies for Durable Control

Strategies described in the research literature include routine viral-load monitoring, improved adherence, drug-resistance genotyping, switching regimens when indicated, and selecting effective antiretroviral combinations. NIH HIVinfo states that resistance testing can identify which medicines will still work and help clinicians choose an effective regimen, while taking medicines exactly as prescribed reduces resistance risk. Contemporary ART regimens generally have high barriers to resistance, but resistance to earlier drugs and uncommon resistance to contemporary ART continue to require careful clinical management.

Research presented from Taiwan indicates a TDR prevalence of 6% among treatment-naive individuals. While subtype B was the most common strain, the study identified specific mutations associated with drug resistance, such as D67N, M184V, and K103N. Continuous monitoring of TDR trends is essential for adapting treatment approaches and maintaining the efficacy of ART.

Future Directions in Combating HIV Drug Resistance

The fight against HIV drug resistance is an ongoing process that requires continuous innovation and adaptation. Several promising strategies are being explored to improve treatment outcomes and prevent the spread of resistant strains. From the use of drugs with higher resistance barrier and next-generation diagnostic tools, the landscape of HIV treatment is set to evolve. In light of growing ART resistance, future innovations such as drugs with new mechanisms of action, personalized medicine are promising strategies. Continuous monitoring and surveillance are key to combating HIV drug resistance and ensuring long term effectiveness of treatment.

AI Search Multiple angles on this topic

The Next Generation of HIV Therapy

A 2025 review describes major advances in antiretroviral therapy that have transformed HIV into a chronic condition. It identifies drug resistance, long-term toxicities, adherence challenges, and persistent viral reservoirs as continuing drivers of innovation. The review focuses on new molecules in clinical development and emerging drug-delivery platforms.

Resistance in Practice

A case report describes how the ART era has brought hope to millions of people and notes that Namibia's Ministry of Health and Social Services implemented HIV treatment guidelines with WHO guidance to standardize and optimize care. A 2026 report on Uganda described a public-health improvement in which overall population prevalence of drug-resistant viraemia declined despite rising pretreatment resistance. These examples show how treatment guidance, program implementation, and resistance patterns can shape real-world outcomes.

Resistance levels differ by treatment history

  • 3.9% to 8.6%; up to 19.6% percentAcross the reported surveys, dolutegravir resistance ranged from 3.9% to 8.6%; among highly treatment-experienced people who switched to a dolutegravir regimen with high viral loads, it reached 19.6%.[1]
  • 50%; 49%; 11%; 1% percentAmong people with HIV treatment failure, pooled acquired resistance prevalence was 50% for NRTIs, 49% for NNRTIs, 11% for protease inhibitors, and 1% for integrase inhibitors.[2]
  • 42.7%; 12.7% percentA meta-analysis found pretreatment drug resistance in 42.7% of children exposed to preventive ART and 12.7% of children not exposed to it.[3]

What resistance estimates reveal about their populations

These figures describe different groups and resistance contexts, rather than a single rate for everyone with HIV. The higher dolutegravir estimate applies to people with extensive prior treatment and high viral loads, so it should not be read as the typical level across all treated people.[1]

The contrast between children exposed and unexposed to preventive ART indicates that pretreatment resistance estimates depend on treatment exposure history. It does not establish that exposure alone accounts for the difference.[3]

How other reports frame resistance

NIH guidance notes that resistance testing after more than four weeks may still help guide therapy, but previously selected mutations can become undetectable when drug pressure is absent. A negative result in that setting therefore may not capture the full history of resistance.[4]

What resistance reports cannot resolve

  • How well do pooled resistance estimates for people experiencing treatment failure represent people whose treatment is still suppressing HIV?[2]
  • How much does the limited number of transmitted-resistance cases in the trial cohort affect confidence in comparisons with other populations?[5]
  • When resistance testing occurs after drug pressure has waned, how often might previously selected mutations no longer be detected?[4]

Sources

  1. HIV drug resistance – brief report 2024 (www.who.int)
  2. Prevalence of acquired and transmitted HIV drug resistance in Iran: a systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)
  3. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel (pmc.ncbi.nlm.nih.gov)
  4. Laboratory Testing: Drug-Resistance Testing | NIH (clinicalinfo.hiv.gov)
  5. HIV drug resistance in a community‐randomized trial of universal testing and treatment: HPTN 071 (PopART) (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What does it mean when someone says HIV has drug resistance, and why should I be concerned?

HIV drug resistance is when the HIV virus mutates, changing its genetic structure in a way that reduces the effectiveness of antiretroviral drugs. This is significant because it can compromise treatment, potentially leading to treatment failure. It is an ongoing concern, especially with the possibility of transmitted drug resistance.

2

What is transmitted drug resistance, and why is it important to know about?

Transmitted drug resistance (TDR) refers to the transmission of HIV strains that are already resistant to one or more antiretroviral drugs from one person to another. Its prevalence impacts the effectiveness of initial treatment regimens, potentially leading to treatment failure and increased healthcare costs. Areas of high TDR may require baseline resistance testing to ensure effective first-line treatment.

3

Why is antiretroviral therapy so important, and how does drug resistance affect it?

Antiretroviral therapy (ART) is crucial in managing HIV by suppressing the virus and preventing disease progression. However, the development of drug resistance can compromise the effectiveness of ART. When resistance occurs, the standard ART regimen may no longer be sufficient to control the virus, necessitating a change in medication or treatment strategy. Without effective ART, the virus can replicate unchecked, leading to disease progression and increased risk of transmission.

4

Are certain types of HIV more likely to become drug-resistant?

Certain HIV subtypes may be more prone to drug resistance than others, highlighting the importance of subtype surveillance. For example, the CRF01_AE subtype showed a high TDR rate. Identifying these associations can help inform tailored prevention and treatment efforts, ensuring that healthcare resources are allocated effectively. Further research is needed to fully understand these associations and their implications for treatment strategies.

5

What are the future strategies for combating HIV drug resistance?

Strategies to combat HIV drug resistance involve continuous monitoring, surveillance, and innovation, including the development of drugs with new mechanisms of action and personalized medicine. Monitoring TDR trends allows for adapting treatment approaches, ensuring the long-term effectiveness of ART. Newer approaches involve drugs with higher resistance barriers and next-generation diagnostic tools.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.